Methylphenobarbital

Methylphenobarbital, also known as mephobarbital, (marketed in the US under the brand name Mebaral by barbiturate derivative.

Methylphenobarbital is used as a sedative, phenobarbital, and has similar indications, therapeutic value, and tolerability.

Approval History

• 1935 Mebaral was introduced by Winthrop Pharmaceuticals.
• 2001 Methylphenobarbital discontinued in the UK.
• 2003 Mebaral acquired by Ovation Pharmaceuticals (specialty pharmaceutical company who acquire underpromoted branded pharmaceutical products).

Overdose symptoms

Symptoms of overdose of metharbital include confusion, decrease in or loss of reflexes, somnolence, pyrexia, irritability, hypothermia, poor judgment, shortness of breath or slow/troubled breathing, slow heartbeat, slurred speech, staggering, trouble in sleeping, unusual movements of the eyes, weakness

References

• The Treatment of Epilepsy 2nd Ed by S. D. Shorvon (Editor), David R. Fish (Editor), Emilio Perucca (Editor), W. Edwin Dodson (Editor). Published by Blackwell 2004. ISBN 0-632-06046-8